Fluorescence Imaging of Adalimumab-680LT in Inflammatory Bowel Disease
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Crohn's Disease (CD) and Ulcerative Colitis (UC) are chronic inflammatory bowel diseases
(IBD). Adalimumab is a human monoclonal antibody against TNF-alpha, a pro-inflammatory
cytokine that mediates the inflammatory response in IBD upon binding to the TNF receptors.
Primary non-response to adalimumab is high in both CD and UC. Currently, there are no
predictors of response to adalimumab and the actual mechanism of action has not yet been
elucidated. To gain better understanding of the drug targeting of adalimumab in IBD, the
University Medical Center Groningen (UMCG) developed fluorescently labeled adalimumab
(adalimumab-680LT). This study aims to assess the safety and the optimal dose of
adalimumab-680LT to visualize and potentially quantify the local drug concentration and
predict treatment response in IBD patients using in vivo and ex vivo fluorescence molecular
imaging (FMI).